The Spine in β-thalassemia syndromes

Spine

Volumn 37, Issue 4, 2012, Pages 334-339

  Haidar, Rachid ^a   Mhaidli, Hani ^b   Musallam, Khaled M ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

back pain; extramedullary hematopoiesis; intervertebral disc degeneration; osteoporosis; scoliosis; spine; thalassemia

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFEROXAMINE; PAMIDRONIC ACID; VITAMIN D; ZINC; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; BACKACHE; BETA THALASSEMIA; CONSERVATIVE TREATMENT; DRUG SAFETY; DRUG USE; GENETIC RISK; HUMAN; HYPOCALCEMIA; INTERVERTEBRAL DISK DEGENERATION; LOW DRUG DOSE; MEDLINE; NONHUMAN; OSTEOPOROSIS; PARASPINAL EXTRAMEDULLARY HEMATOPOIESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCOLIOSIS; SPINE DISEASE; SYSTEMATIC REVIEW; THALASSEMIA INDUCED OSTEOPOROSIS; THALASSEMIA MAJOR; UNSPECIFIED SIDE EFFECT;

BACK PAIN; BETA-THALASSEMIA; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COMORBIDITY; DIPHOSPHONATES; HUMANS; INTERVERTEBRAL DISC DEGENERATION; OSTEOPOROSIS; RISK FACTORS; SPINAL DISEASES; SPINE;

EID: 84857787691     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31821bd095     Document Type: Review

References (80)

1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Oxford : Blackwell Science ; 2001 .
2. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009 ;33(suppl 1): S46 - 57 .
3. Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin 2009 ;33(suppl 1): S58 - 69 .
4. Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009 ; 122 : 165-73 .
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004 ; 89 : 1187-93 . (Pubitemid 39390442)
6. Cappellini MD, Musallam KM, Taher AT. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin 2009 ;33(suppl 1): S145 - 59 .
7. Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J 2010 ; 19 : 871-8 .
8. Lasco A, Morabito N, Gaudio A, et al. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001 ; 12 : 570-5 . (Pubitemid 32777434)
9. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 2004 ; 74 : 68-71 . (Pubitemid 38166607)
10. Karimi M, Ghiam AF, Hashemi A, et al. Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr 2007 ; 44 : 29-32 . (Pubitemid 46168872)
11. Jensen CE, Tuck SM, Agnew JE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998 ; 103 : 911-5 . (Pubitemid 29012624)
12. Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003 ;3:4.
13. Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. Bone mineral density in Iranian adolescents and young adults with betathalassemia major. Pediatr Hematol Oncol 2007 ; 24 : 469-79 . (Pubitemid 47360014)
14. Vogiatzi MG, Autio KA, Mait JE, et al. Low bone mineral density in adolescents with beta-thalassemia. Ann N Y Acad Sci 2005 ; 1054 : 462-6 . (Pubitemid 43031057)
15. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004 ; 127 : 127-39 . (Pubitemid 39371805)
16. Guzeloglu-Kayisli O, Cetin Z, Keser I, et al. Relationship between SP1 polymorphism and osteoporosis in beta-thalassemia major patients. Pediatr Int 2008 ; 50 : 474-6 .
17. Pietrapertosa AC, Minenna G, Colella SM, et al. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. Panminerva Med 2009 ; 51 : 17-23 .
18. Napoli N, Carmina E, Bucchieri S, et al. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006 ; 38 : 888-92 . (Pubitemid 44498594)
19. Pratelli L, Verri E, Fortini M, et al. Chelation therapy and bone metabolism markers in thalassemia major. J Pediatr Endocrinol Metab 2006 ; 19 : 1335-42 . (Pubitemid 44963844)
20. Scacchi M, Danesi L, Cattaneo A, et al. Growth hormone defi ciency (GHD) in adult thalassaemic patients. Clin Endocrinol (Oxf) 2007 ; 67 : 790-5 . (Pubitemid 47620448)
21. Scacchi M, Danesi L, Cattaneo A, et al. Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol (Oxf) 2008 ; 69 : 202-7 . (Pubitemid 352009023)
22. Mahachoklertwattana P, Pootrakul P, Chuansumrit A, et al. Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab 2006 ; 24 : 146-52 .
23. Eren E, Yilmaz N. Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassaemia major. Int J Clin Pract 2005 ; 59 : 46-51 . (Pubitemid 40260113)
24. Voskaridou E, Christoulas D, Xirakia C, et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009 ; 94 : 725-8 .
25. Angelopoulos NG, Goula A, Katounda E, et al. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Pediatr Hematol Oncol 2007 ; 24 : 481-91 . (Pubitemid 47360016)
26. Angelopoulos NG, Goula A, Katounda E, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. J Bone Miner Metab 2007 ; 25 : 60-7 . (Pubitemid 46012998)
27. Lasco A, Morabito N, Gaudio A, et al. Osteoporosis and betathalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 2002 ; 25 : 338-44 . (Pubitemid 34436129)
28. Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004 ; 19 : 722-7 . (Pubitemid 41094382)
29. Morabito N, Russo GT, Gaudio A, et al. The "lively" cytokines network in beta-thalassemia major-related osteoporosis. Bone 2007 ; 40 : 1588-94 . (Pubitemid 46766649)
30. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 ; 397 : 315-23 .
31. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE defi ciency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000 ; 97 : 10905-10 .
32. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-defi cient mice develop early onset osteoporosis and arterial calcifi cation. Genes Dev 1998 ; 12 : 1260-8 . (Pubitemid 28213402)
33. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003 ; 123 : 730-7 . (Pubitemid 37468072)
34. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol 2005 ; 74 : 359-61 . (Pubitemid 40461158)
35. Mylona M, Leotsinides M, Alexandrides T, et al. Comparison of DXA, QCT and trabecular structure in beta-thalassaemia. Eur J Haematol 2005 ; 74 : 430-7 . (Pubitemid 40545569)
36. Angelopoulos NG, Katounda E, Rombopoulos G, et al. Evaluation of bone mineral density of the lumbar spine in patients with beta-thalassemia major with dual-energy x-ray absorptiometry and quantitative computed tomography: a comparison study. J Pediatr Hematol Oncol 2006 ; 28 : 73-8 .
37. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993 ; 341 : 801-5 . (Pubitemid 23096296)
38. Soliman AT, El Banna N, Abdel Fattah M, et al. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998 ; 47 : 541-8 . (Pubitemid 28213114)
39. Anapliotou ML, Kastanias IT, Psara P, et al. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf) 1995 ; 42 : 279-87 .
40. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002 ; 13 : 644-9 .
41. Pennisi P, Pizzarelli G, Spina M, et al. Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 2003 ; 21 : 402-8 . (Pubitemid 38017697)
42. Perifanis V, Vyzantiadis T, Vakalopoulou S, et al. Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. Br J Haematol 2004 ; 125 : 91-2 . (Pubitemid 38453285)
43. Perifanis V, Vyzantiadis T, Tziomalos K, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 2007 ; 86 : 23-30 . (Pubitemid 46138314)
44. Otrock ZK, Azar ST, Shamseddeen WA, et al. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 2006 ; 85 : 605-9 . (Pubitemid 44283081)
45. Otrock ZK, Mahfouz RA, Charafeddine KM, et al. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann Hematol 2008 ; 87 : 947-8 .
46. Gilfi llan CP, Strauss BJ, Rodda CP, et al. A randomized, doubleblind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 2006 ; 79 : 138-44 . (Pubitemid 44440441)
47. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebocontrolled trial. Haematologica 2006 ; 91 : 1193-202 . (Pubitemid 44408429)
48. Voskaridou E, Christoulas D, Konstantinidou M, et al. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 2008 ; 93 : 1588-90 .
49. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 2010 ; 21 : 183-7 .
50. Onur O, Sivri A, Gumruk F, et al. Beta thalassaemia: a report of 20 children. Clin Rheumatol 1999 ; 18 : 42-4 . (Pubitemid 29104752)
51. Desigan S, Hall-Craggs MA, Ho CP, et al. Degenerative disc disease as a cause of back pain in the thalassaemic population: a casecontrol study using MRI and plain radiographs. Skeletal Radiol 2006 ; 35 : 95-102 . (Pubitemid 43125641)
52. Trachtenberg F, Foote D, Martin M, et al. Pain as an emergent issue in thalassemia. Am J Hematol 2010 ; 85 : 367-70 .
53. Roger E, Letts M. Sickle cell disease of the spine in children. Can J Surg 1999 ; 42 : 289-92 . (Pubitemid 29385853)
54. De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988 ; 113 : 661-9 .
55. Brill PW, Winchester P, Giardina PJ, et al. Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol 1991 ; 156 : 561-5 .
56. Chan YL, Li CK, Pang LM, et al. Desferrioxamine-induced long bone changes in thalassaemic patients-radiographic features, prevalence and relations with growth. Clin Radiol 2000 ; 55 : 610-4 . (Pubitemid 32054585)
57. Hartkamp MJ, Babyn PS, Olivieri F. Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. Pediatr Radiol 1993 ; 23 : 525-8 . (Pubitemid 24031057)
58. Naselli A, Vignolo M, Di Battista E, et al. Long-term follow-up of skeletal dysplasia in thalassaemia major. J Pediatr Endocrinol Metab 1998 ;11(suppl 3): 817-25 .
59. Levin TL, Sheth S, Berdon WE, et al. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients. Pediatr Radiol 1995 ;25(suppl 1): S122 - 4 . (Pubitemid 26003477)
60. Grinberg LN, Rachmilewitz EA, Kitrossky N, et al. Hydroxyl radical generation in beta-thalassemic red blood cells. Free Radic Biol Med 1995 ; 18 : 611-5 .
61. Yamaza T, Masuda KF, Atsuta I, et al. Oxidative stress-induced DNA damage in the synovial cells of the temporomandibular joint in the rat. J Dent Res 2004 ; 83 : 619-24 . (Pubitemid 41766070)
62. Hall-Craggs MA, Porter J, Gatehouse PD, et al. Ultrashort echo time (UTE) MRI of the spine in thalassaemia. Br J Radiol 2004 ; 77 : 104-10 . (Pubitemid 38313222)
63. Korovessis P, Papanastasiou D, Tiniakou M, et al. Incidence of scoliosis in beta-thalassemia and follow-up evaluation. Spine (Phila Pa 1976) 1996 ; 21 : 1798-801 . (Pubitemid 26260297)
64. Korovessis PG, Papanastasiou D, Tiniakou M, et al. Prevalence of scoliosis in beta-thalassemia. J Spinal Disord 1996 ; 9 : 170-3 .
65. Papageorgiou O, Papanastasiou DA, Beratis NG, et al. Scoliosis in beta thalassemia. Pediatrics 1991 ; 88 : 341-5 .
66. Papanastasiou DA, Baikousis A, Sdougos G, et al. Correlative analysis of the sagittal profi le of the spine in patients with betathalassemia and in healthy persons. J Spinal Disord 2000 ; 13 : 113-7 .
67. Papanastasiou DA, Ellina A, Baikousis A, et al. Natural history of untreated scoliosis in beta-thalassemia. Spine (Phila Pa 1976) 2002 ; 27 : 1186-90 . (Pubitemid 34596337)
68. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006 ; 37 : 12-20 . (Pubitemid 44062361)
69. Lau SK, Chan CK, Chow YY. Cord compression due to extramedullary hemopoiesis in a patient with thalassemia. Spine (Phila Pa 1976) 1994 ; 19 : 2467-70 . (Pubitemid 24347185)
70. Coskun E, Keskin A, Suzer T, et al. Spinal cord compression secondary to extramedullary hematopoiesis in thalassemia intermedia. Eur Spine J 1998 ; 7 : 501-4 . (Pubitemid 29009748)
71. Ileri T, Azik F, Ertem M, et al. Extramedullary hematopoiesis with spinal cord compression in a child with thalassemia intermedia. J Pediatr Hematol Oncol 2009 ; 31 : 681-3 .
72. Chehal A, Aoun E, Koussa S, et al. Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine (Phila Pa 1976) 2003 ; 28 : E245 - 9 .
73. Tai SM, Chan JS, Ha SY, et al. Successful treatment of spinal cord compression secondary to extramedullary hematopoietic mass by hypertransfusion in a patient with thalassemia major. Pediatr Hematol Oncol 2006 ; 23 : 317-21 .
74. Dore F, Cianciulli P, Rovasio S, et al. Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. Ann Ital Med Int 1992 ; 7 : 137-40 .
75. Jackson DV Jr, Randall ME, Richards F II. Spinal cord compression due to extramedullary hematopoiesis in thalassemia: long-term follow-up after radiotherapy. Surg Neurol 1988 ; 29 : 389-92 .
76. Amirjamshidi A, Abbassioun K, Ketabchi SE. Spinal extradural hematopoiesis in adolescents with thalassemia. Report of two cases and a review of the literature. Childs Nerv Syst 1991 ; 7 : 223-5 .
77. Luitjes WF, Braakman R, Abels J. Spinal cord compression in a new homozygous variant of beta-thalassemia. Case report. J Neurosurg 1982 ; 57 : 846-8 . (Pubitemid 13208302)
78. Mann KS, Yue CP, Chan KH, et al. Paraplegia due to extramedullary hematopoiesis in thalassemia. Case report. J Neurosurg 1987 ; 66 : 938-40 . (Pubitemid 17085719)
79. Tan TC, Tsao J, Cheung FC. Extramedullary haemopoiesis in thalassemia intermedia presenting as paraplegia. J Clin Neurosci 2002 ; 9 : 721-5 . (Pubitemid 35364758)
80. Salehi SA, Koski T, Ondra SL. Spinal cord compression in betathalassemia: case report and review of the literature. Spinal Cord 2004 ; 42 : 117-23 . (Pubitemid 38250834)